lundi 3 décembre 2018

Onco Actu du 3 décembre 2018


1. Biologie

The long and short of CDK12 [MIT News]

1.4 Biologie - Technos

Genetically Modified People Are Walking Among Us [NY Times]

3.4 Chimioprévention

Why high risk women are reluctant to take breast cancer drug [University of Leeds]

Women reveal reasons they reject a preventive treatment for breast cancer [Cancer Research UK]

4.12 Biopsies liquides

Blood test could predict if chemotherapy will work for advanced prostate cancer patients [Garvan Institute]

4.2 Dép., diag. & prono. - Génome

Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery [NCI]

5. Traitements

Blasting radiation therapy into the future: New systems may improve cancer treatment [Stanford Medicine]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma [Celgene]

5.12.3 Immunothérapies-combinaisons

CRI study highlights CTLA-4’s marquee role in PD-1/L1 combos — despite an increasingly troubled clinical profile [EndPoints]

5.12.8 Immunothérapies - Economie

BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse [FiercePharma]

5.2.1 Pharma - Partenariats

Dutch firm argenx, J&J affiliate to collaborate on cancer therapy [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

GSK buys cancer biotech Tesaro for $5.1B [STAT]

GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company [GSK]

5.2.3 Pharma - économie

Prepping for key ASH presentation, little Aprea Therapeutics gets $57M to fuel PhIII p53 cancer study [EndPoints]

5.8.7 ASH - Lymphomes

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma [Roche]

6. Lutte contre les cancers

Proton beam failure leaves hundreds of child cancer patients at risk [The Telegraph]

6.4 Médico-éco

Can better cancer care lower company's health costs? [Reuters]